The last ten years have seen a notable increase in balloon pulmonary angioplasty safety.

Published Date: 23 Apr 2023

The treatment of chronic thromboembolic pulmonary hypertension with balloon pulmonary angioplasty has an evolving safety profile over the years, from 2013 to 2022, as revealed by an analysis of more than two dozen studies.

Read Full News

Latest News

COPD in 2025: Year in Review

COPD in 2025: Year in Review

Characterizing COPD - Lung Cancer Patients, with Joseph Friedberg, MD Joseph Friedberg, MD, Kevin Kunzmann

Friedberg discusses the inconsistent clinical pathways from disease progression to intervention in patients with a pair of highly deadly lung diseases.

Post-NICU PM2.5 Exposure Raises Asthma Risk in Children With Bronchopulmonary Dysplasia

Post-NICU PM2.5 Exposure Raises Asthma Risk in Children With Bronchopulmonary Dysplasia

Asthma Biologic Adherence Shaped by Psychological, Clinical, Systemic Factors

Asthma Biologic Adherence Shaped by Psychological, Clinical, Systemic Factors

FDA Approves Nerandomilast (Jascayd) Tablets for Progressive Pulmonary Fibrosis

FDA Approves Nerandomilast (Jascayd) Tablets for Progressive Pulmonary Fibrosis

Sleep Disorders Linked to Poorer Symptom Control in Severe Asthma

Sleep Disorders Linked to Poorer Symptom Control in Severe Asthma

Todays Updates

Adults with Developmental and Epileptic Encephalopathies in the Precision Treatment Era Danielle Andrade, MD, MSc

Explore the evolving landscape of developmental and epileptic encephalopathies in adults, highlighting precision therapies and the need for accurate diagnoses.

What’s All the Buzz? Trending Topics and Phrases of Neurology in 2025 Marco Meglio

Explore the transformative buzzwords in neurology for 2025, highlighting advancements in AI, gene therapy, personalized treatment, and neuroplasticity.

Todays Updates

Adults with Developmental and Epileptic Encephalopathies in the Precision Treatment Era Danielle Andrade, MD, MSc

Explore the evolving landscape of developmental and epileptic encephalopathies in adults, highlighting precision therapies and the need for accurate diagnoses.

What’s All the Buzz? Trending Topics and Phrases of Neurology in 2025 Marco Meglio

Explore the transformative buzzwords in neurology for 2025, highlighting advancements in AI, gene therapy, personalized treatment, and neuroplasticity.

Latest News

COPD in 2025: Year in Review

Friedberg discusses the inconsistent clinical pathways from disease progression to intervention in patients with a pair of highly deadly lung diseases.

Post-NICU PM2.5 Exposure Raises Asthma Risk in Children With Bronchopulmonary Dysplasia

Asthma Biologic Adherence Shaped by Psychological, Clinical, Systemic Factors

FDA Approves Nerandomilast (Jascayd) Tablets for Progressive Pulmonary Fibrosis

Sleep Disorders Linked to Poorer Symptom Control in Severe Asthma

News All Time

Tezepelumab Drastically Reduces OCS Use for Asthma in Open-Label Trial

Tezepelumab Drastically Reduces OCS Use for Asthma in Open-Label Trial

How to Set a Biologic Strategy for Asthma, with Sara Assaf, MD Sara Assaf, MD

Assaf shares insights into how to navigate patient profiles and treatment options to optimize severe asthma care with biologics.

Exploring the New COPD Era: Biologics, Guidelines, and Real-World Barriers

Exploring the New COPD Era: Biologics, Guidelines, and Real-World Barriers

Lungcast: Resilience and Sustainability: Preparing Healthcare for the Future with Elizabeth Cerceo, MD Albert Rizzo, MD, Elizabeth Cerceo, MD

This episode of Lungcast features a discussion on emerging treatment approaches for SCLC.

Long-Term Data Support New Zopapogene Imadenovec Approval for RRP Victoria Johnson

New long-term data reveals that Papzimeos offers sustained relief for adults with recurrent respiratory papillomatosis, reducing the need for surgeries.

Nerandomilast Approval Breaks Decade-Long Dry Spell for IPF, With Toby Maher, MD, PhD Toby Maher, MD, PhD

Maher discussed the new FDA approved drug, marketed as Jascayd, and its impact for idiopathic pulmonary fibrosis.

Mucoactives Found to Have Little Benefit for Bronchiectasis Victoria Johnson

A recent study reveals that hypertonic saline and carbocisteine do not effectively reduce pulmonary exacerbations.

FDA Accepts NDA for Chiesi’s Single Inhaler Triple Therapy for Asthma Victoria Johnson

The therapy is currently approved in almost 50 countries under the name Trimbow.

FDA Approval Adds Tezepelumab to CRSwNP Treatment Landscape Victoria Johnson

Tezepelumab is the first TSLP-targeting biologic to be approved for chronic rhinosinusitis with nasal poylps.

Sleep Apnea Significantly Impacts Mortality Benefit of GLP-1s Kevin Kunzmann

CHEST 2025 data suggest OSA is an "effect modifier" on the mortality benefit of GLP-1 receptor agonists in patients co-diagnosed with type 2 diabetes.

4 Trials That May Change Pulmonary Embolism, with Parth Rali, MD Parth Rali, MD

Rali highlights a series of randomized, controlled trials that could reinvigorate the recently stagnant field of PE treatment development.

Redefining Severe Airway Disease Care: Clinicians Weigh In on Biologics and Barriers Victoria Johnson

Experts explore the evolution of asthma and COPD treatments with targeted biologic therapies.

The Case for More Spirometry, Pulmonary Function Testing, with Meredith McCormack, MD Kevin Kunzmann

McCormack believes simple lung function results accrued over a lifetime can optimize an individual's pulmonary care.

Dupilumab, Tezepelumab Provide Consistent Real-World Severe Asthma Outcomes Kevin Kunzmann

Retrospective cohort data at CHEST 2025 show the similar efficacy profiles — but slightly different safety outcomes — among patients receiving either biologic.

Opportunities to Define and Treat Indoor Air Quality, with Sarath Raju, MD, MPH Sarath Raju, MD, MPH

Most clinicians are not considering poor home air exposure when treating persistent asthma or airway disease, Raju explains. That may be making a difference in outcomes.

What Ails Lung Cancer Screening, with Douglas Wood, MD Douglas Wood, MD

Wood shares 3 factors that influencing our nationally poor rates of high-risk lung cancer screening.

Recommended News For You

Hydroxyurea Shows Some Benefits in Milder Sickle Cell Disease

Lentiviral Gene Therapy Shows Promise in Severe Hemophilia A

Liver cancer cells under pressure: Compression can spark invasion, drug resistance and altered gene activity

Tumor infiltration of major blood vessels, not metastasis, may be primary cause of cancer death

Significant worldwide disparities seen in availability and timeliness of new cancer drugs

FDA Approves New Bladder Cancer First-Line Standard of Care.

While most cancer screenings won't prolong lives, there are still good reasons to continue screening.

Recommended Articles For You

Advancing Oncology Careers with Education, Workflow Tools, and Clinical Resources 

Advancing Medical Oncology: Education, Certification, Clinical Trials, and Evolving Treatment Pathways 

What is Red Cell Distribution Width and Why Should You Care? 

Cancer Diagnosis in 2025: Innovations, Education, and Evolving Clinical Strategies 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

When it comes to LBCL relapse in complete remission, ASCT outperforms CAR T-cell therapy.

2.

Minimally invasive prostate cancer treatment shows success in first patient

3.

Poor agreement between diagnostic tests for breast cancer-related lymphedema

4.

A protein with new anticancer activity has been identified

5.

Reversing the toxic relationship with high doses of chemotherapy in oncology.

1.

Unlocking the Potential of Lymphocytes: Exploring the Role of These Immune System Cells

2.

Unlocking the Potential of Sarclisa: A New Hope for Cancer Treatment

3.

The Growing Challenge of Haematological Malignancies in Older Adults

4.

Thyroid Cancer and Insulin Resistance: Unraveling the Complex Interplay for Better Patient Outcomes

5.

Anemia in Older Adults: Causes, Clinical Impact, and Evidence-Based Management

1.

International Lung Cancer Congress®

2.

Future NRG Oncology Meeting

3.

Genito-Urinary Oncology Summit 2026

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Expert Group meeting with the management of EGFR mutation positive NSCLC - Part III

2.

CDK4/6 Inhibitors in Extending Overall Survival in HR+/HER2- aBC Patients in Clinical Trial and Real World

3.

An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- The Conclusion

4.

Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part I

5.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part IV

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot